Department of Cardiology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.
Seven Summit Treks, Kathmandu, Nepal.
JAMA Cardiol. 2024 May 1;9(5):480-485. doi: 10.1001/jamacardio.2024.0364.
Arterial hypoxemia, electrolyte imbalances, and periodic breathing increase the vulnerability to cardiac arrhythmia at altitude.
To explore the incidence of tachyarrhythmias and bradyarrhythmias in healthy individuals at high altitudes.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study involved healthy individuals at altitude (8849 m) on Mount Everest, Nepal. Recruitment occurred from January 25 to May 9, 2023, and data analysis took place from June to July 2023.
All study participants underwent 12-lead electrocardiogram, transthoracic echocardiography, and exercise stress testing before and ambulatory rhythm recording both before and during the expedition.
The incidence of a composite of supraventricular (>30 seconds) and ventricular (>3 beats) tachyarrhythmia and bradyarrhythmia (sinoatrial arrest, second- or third-degree atrioventricular block).
Of the 41 individuals recruited, 100% were male, and the mean (SD) age was 33.6 (8.9) years. On baseline investigations, there were no signs of exertional ischemia, wall motion abnormality, or cardiac arrhythmia in any of the participants. Among 34 individuals reaching basecamp at 5300 m, 32 participants climbed to 7900 m or higher, and 14 reached the summit of Mount Everest. A total of 45 primary end point-relevant events were recorded in 13 individuals (38.2%). Forty-three bradyarrhythmic events were documented in 13 individuals (38.2%) and 2 ventricular tachycardias in 2 individuals (5.9%). Nine arrhythmias (20%) in 5 participants occurred when climbers were using supplemental bottled oxygen, whereas 36 events (80%) in 11 participants occurred at lower altitudes when no supplemental bottled oxygen was used. The proportion of individuals with arrhythmia remained stable across levels of increasing altitude, while event rates per 24 hours numerically increased between 5300 m (0.16 per 24 hours) and 7300 m (0.37 per 24 hours) before decreasing again at higher altitudes, where supplemental oxygen was used. None of the study participants reported dizziness or syncope.
In this study, more than 1 in 3 healthy individuals experienced cardiac arrhythmia during the climb of Mount Everest, thereby confirming the association between exposure to high altitude and incidence of cardiac arrhythmia. Future studies should explore the potential implications of these rhythm disturbances.
动脉低氧血症、电解质失衡和周期性呼吸会增加在高海拔地区发生心律失常的脆弱性。
探讨健康个体在高海拔地区的心动过速和心动过缓的发生率。
设计、地点和参与者:本前瞻性队列研究纳入了尼泊尔珠穆朗玛峰海拔 8849 米处的健康个体。招募时间为 2023 年 1 月 25 日至 5 月 9 日,数据分析时间为 2023 年 6 月至 7 月。
所有研究参与者在攀登珠穆朗玛峰前(海拔 8849 米)接受了 12 导联心电图、经胸超声心动图和运动应激试验,并在探险前和期间进行了动态心电图记录。
复合性(超过 30 秒)和室性(超过 3 次)心动过速和心动过缓(窦性停搏、二度或三度房室传导阻滞)的发生率。
在招募的 41 名个体中,100%为男性,平均(标准差)年龄为 33.6(8.9)岁。在基线研究中,没有任何参与者出现运动性缺血、壁运动异常或心律失常的迹象。在 34 名到达海拔 5300 米大本营的参与者中,32 名参与者攀登到 7900 米或更高,14 名到达珠穆朗玛峰峰顶。共有 45 名主要终点相关事件记录在 13 名参与者(38.2%)中。43 例心动过缓事件记录在 13 名参与者(38.2%)中,2 例室性心动过速记录在 2 名参与者(5.9%)中。9 例(20%)心律失常发生在 5 名使用补充瓶装氧气的登山者中,而 36 例(80%)事件发生在 11 名使用补充瓶装氧气的参与者中,当时的海拔较低。随着海拔的升高,心律失常的个体比例保持稳定,而每 24 小时的事件发生率在 5300 米(0.16 次/24 小时)和 7300 米(0.37 次/24 小时)之间增加,然后在使用补充氧气的较高海拔再次下降。没有研究参与者报告头晕或晕厥。
在这项研究中,超过 1/3 的健康个体在攀登珠穆朗玛峰期间经历了心律失常,从而证实了暴露于高海拔与心律失常发生率之间的关联。未来的研究应探讨这些节律紊乱的潜在影响。